inbrx-101/rhaat-fc
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03815396)
Timeline
Indications
Mechanism of action
- Alpha-1-antitrypsinINHIBITOR
SERPINA1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05897424 | Phase 2 | Jan 31, 2024 | Inhibrx, Inc. |
| NCT05856331 | Phase 2 | Oct 12, 2023 | Inhibrx, Inc. |
| NCT03815396 | Phase 1 | Jun 30, 2019 | Inhibrx, Inc., Union Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inhibrx, Inc. | For profit | 3 | 3 | 2 | 2019 |
| Union Therapeutics | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1